Evidence map›Paper›PMID 42294265›Full record

ArticleFrontiers in oncology2026

Case Report: Erdheim-Chester disease with liver involvement successfully treated with trametinib.

Long Chang, Kai-Ni Shen, Ya-Ping Luo, Xin-Xin Cao

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Long Chang *Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Kai-Ni Shen *Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ya-Ping LuoState Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China.
Xin-Xin CaoDepartment of Medical Oncology, National Cancer Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Erdheim-Chester disease (ECD) is a rare form of histiocytosis with various clinical manifestations. Liver involvement has been infrequently reported. Case presentation: We report a case of ECD with liver involvement, presenting with progressive elevation of liver enzymes, a manifestation rarely reported in the literature. Follow-up liver function testing and FAPI-PET/CT performed 6 months after initiation of trametinib therapy demonstrated a dramatic response. Conclusion: Trametinib holds promise as a therapeutic option for patients with non-BRAF-V600E mutant ECD presenting with liver involvement.

Indexed as

Erdheim–Chester diseasehistiocytosisliver functionliver involvementtrametinib

Identifiers

PMID42294265
PMCPMC13259678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.